<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544309</url>
  </required_header>
  <id_info>
    <org_study_id>0059</org_study_id>
    <nct_id>NCT01544309</nct_id>
  </id_info>
  <brief_title>LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts</brief_title>
  <acronym>LISTEN</acronym>
  <official_title>Study on Effect of Highly Potent Statins on Lipid Lowering Effect and Glucose Metabolism in Hypercholesterolemia Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Listen Trial Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Listen Trial Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid
      lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level</measure>
    <time_frame>Baseline, and 12 months after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c Level</measure>
    <time_frame>Baseline, 12 months after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Deterioration of Diabetic Treatment Status</measure>
    <time_frame>Baseline, 12 months after administration</time_frame>
    <description>&quot;Deterioration of diabetic treatment status&quot; is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration</time_frame>
    <description>&quot;Deterioration of diabetic treatment status&quot; is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in 1,5-AG Level</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
    <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c Level</measure>
    <time_frame>Baseline, 3, 6 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Blood Glucose Level (Fasting)</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Glucose Level (Fasting)</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Insulin Level</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
    <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Level</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
    <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)</measure>
    <time_frame>From the start of the treatment to the end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C Level</measure>
    <time_frame>Baseline, 3 and 6 months after administration, the end of starting dose and the end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in Lipids and Inflammatory Marker (Hs-CRP) and Their Correlation</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment</time_frame>
    <description>Correlation between percent changes in lipids (LDL-C, HDL-C, non-HDL-C, TG, non-HDL-C/HDL-C ratio, LDL-C/HDL-C ratio, TC and FFA) and inflammatory marker (hs-CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007</measure>
    <time_frame>3 months after administration, the end of starting dose and the end of study treatment</time_frame>
    <description>Percentage of participants achieving the target LDL-C levels &lt;100 mg/dL for participants with history of coronary artery diseases (CAD) and &lt;120 mg/dL for participants without history of CAD are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1,5-AG Level</measure>
    <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
    <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1049</enrollment>
  <condition>Hypercholesterolemia With Concomitant Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Atorvastatin administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)</description>
    <arm_group_label>Atorvastatin administration group</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)</description>
    <arm_group_label>Rosuvastatin administration group</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hypercholesterolemia patients

             • Patients who have not achieved the target control levels of LDL-C in the &quot;Japan
             Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular
             Diseases 2007&quot;

          2. Type 2 diabetes patients

               -  Patients diagnosed with type 2 diabetes and receiving diet therapy, exercise
                  therapy, or medication

               -  Patients who received constant therapy for three months before registration and
                  have no plan for therapy change

               -  Patients with kept HbA1c level (Japan Diabetes Society [JDS] level) of less than
                  7.0% (or, National Glycohemoglobin Standardization Program [NGSP] level of less
                  than 7.4%) within three months before registration

               -  Patients receiving or not receiving medication at present

          3. Patients giving voluntary written consent to participate in the study

          4. Male or female patients at 20 years or older

        Exclusion Criteria:

          1. Patients who administered rosuvastatin, atorvastatin or ezetimibe within three month
             at the registration

          2. Patients with severe hypertension (systolic blood pressure [SBP] ≥ 180 mmHg or
             diastolic blood pressure [DBP] ≥ 110 mmHg)

          3. Patients with type 1 diabetes

          4. Patients judged to have familial hypercholesterolemia

          5. Patients with a serum triglyceride level of ≥ 400 mg/dL

          6. Patients who had the onset of cardiovascular or cerebrovascular disease within three
             months

          7. Patients with serious heart failure (NYHA classification III - IV)

          8. Patients with a history of hypersensitivity to statins

          9. Patients with a history of drug-induced myopathy

         10. Patients with severe complication of diabetes

         11. Patients receiving insulin

         12. Patients with serious liver or kidney disease

         13. Patients with serious concurrent disease such as malignancy, or patients with severely
             limited lifespan

         14. Patients who are or may be pregnant

         15. Patients judged by the investigators to be ineligible for participation in the study
             for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisao Ogawa, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiramitsu Heart Clinic</name>
      <address>
        <city>Nagoya city</city>
        <state>Aichi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honjo Daiichi Hospital</name>
      <address>
        <city>Yurihonjo city</city>
        <state>Akita pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iryouhoujin Syadan Yanagisawakai Yanagisawa Iin</name>
      <address>
        <city>Matsudo city</city>
        <state>Chiba pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuno Medical Clinic</name>
      <address>
        <city>Iyo gun</city>
        <state>Ehime pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishite Matsumoto Naika Junkanki Clinic</name>
      <address>
        <city>Matsuyama city</city>
        <state>Ehime pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime Medical CO OP Izumigawa Clinic</name>
      <address>
        <city>Niihama city</city>
        <state>Ehime pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Chuoh Clinic</name>
      <address>
        <city>Fukui city</city>
        <state>Fukui pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka City Medical Association Hospital</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsumoto Clinic</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saku Hospital</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soejima Medical Clinic</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takei's Clinic Internal Medicine</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Cardiovascular Clinic</name>
      <address>
        <city>Itoshima city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morizono Naika</name>
      <address>
        <city>Kitakyushu city</city>
        <state>Fukuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seino Internal Medicine Clinic</name>
      <address>
        <city>Koriyama city</city>
        <state>Fukushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawade Iin</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <zip>Japan</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hashimoto Naika Clinic</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iinuma Iin</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishimura Clinic</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawai Clinic</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niimi Clinic</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takai Clinic</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobayashi Internal Medicine</name>
      <address>
        <city>Kakamigahara city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horibe Clinic</name>
      <address>
        <city>Motosu city</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kondo Cardiovascular Clinic</name>
      <address>
        <city>Ogaki</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshida Naika</name>
      <address>
        <city>Ogaki</city>
        <state>Gifu pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kogure Clinic</name>
      <address>
        <city>Maebashi city</city>
        <state>Gunma pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakano Clinic</name>
      <address>
        <city>Shibukawa city</city>
        <state>Gunma pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshii Central Clinic</name>
      <address>
        <city>Takasaki city</city>
        <state>Gunma pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shigenobu Clinic</name>
      <address>
        <city>Miyoshi city</city>
        <state>Hiroshima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takahashi Kiyohito Clinic</name>
      <address>
        <city>Hakodate city</city>
        <state>Hokkaido pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokuto Internal Medicine Clinic</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katsuya Clinic</name>
      <address>
        <city>Amagasaki city</city>
        <state>Hyogo pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakatani Hospital</name>
      <address>
        <city>Himeji city</city>
        <state>Hyogo pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosumo Clinic</name>
      <address>
        <city>Kako gun</city>
        <state>Hyogo pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harima Clinic</name>
      <address>
        <city>Kakogawa</city>
        <state>Hyogo pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kusunose Clinic</name>
      <address>
        <city>Kobe city</city>
        <state>Hyogo pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yanagi Medical Clinic</name>
      <address>
        <city>Hakusan city</city>
        <state>Ishikawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okyozuka Clinic</name>
      <address>
        <city>Ishikawa gun</city>
        <state>Ishikawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doniwa Clinic</name>
      <address>
        <city>Kanazawa city</city>
        <state>Ishikawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakasa Medical Clinic</name>
      <address>
        <city>Kanazawa city</city>
        <state>Ishikawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Association Medical Corporation Neurology Internal Medicine Kanamori Clinic</name>
      <address>
        <city>Iwate gun</city>
        <state>Iwate pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kuon-kai Kamata Medical Clinic</name>
      <address>
        <city>Morioka city</city>
        <state>Iwate pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Clinic</name>
      <address>
        <city>Marugame city</city>
        <state>Kagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasegawa Outpatients Clinic for Cardiovascular Disease</name>
      <address>
        <city>Takamatsu city</city>
        <state>Kagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tempozan Naika Clinic</name>
      <address>
        <city>Kagoshima city</city>
        <state>Kagoshima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kashiwagi Clinic</name>
      <address>
        <city>Ayase city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Diabetes Clinic</name>
      <address>
        <city>Chigasaki city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takada Internal Medicine Clinic</name>
      <address>
        <city>Hiratsuka city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iroden Clinic</name>
      <address>
        <city>Kamakura city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasu Clinic</name>
      <address>
        <city>Kamakura city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobayashi Hospital</name>
      <address>
        <city>Odawara city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakuai Iin</name>
      <address>
        <city>Sagamihara city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamamoto Clinic</name>
      <address>
        <city>Sagamihara city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arima Clinic</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kikuchi Clinic</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miho cho Cardiovascular Medical Clinic</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamisawa Clinic</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimokurata Heart Clinic</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Sotetsu Bldg. Clinic of Internal Medicine</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Clinic Diabetes Care Center</name>
      <address>
        <city>Kumamoto city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maki Cardiovascular Clinic</name>
      <address>
        <city>Kumamoto city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munakata Clinic</name>
      <address>
        <city>Kumamoto city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terao Hospital</name>
      <address>
        <city>Kumamoto city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashi Diabetes and Cardiovascular Clinic</name>
      <address>
        <city>Tamana city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuo Clinic</name>
      <address>
        <city>Tamana city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Clinic Cardiovascular Medicine</name>
      <address>
        <city>Yatsushiro city</city>
        <state>Kumamoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sawai Naika Iin</name>
      <address>
        <city>Kyotanabe city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asamoto Internal Medical Clinic</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ijinkai Takeda General Hospital</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koseikai Clinic</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakabe International Clinic</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takenaka Clinic</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tegoshi Clinic</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwasaki Hospital</name>
      <address>
        <city>Tsu city</city>
        <state>Mie pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Clinic</name>
      <address>
        <city>Miyazaki city</city>
        <state>Miyazaki pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokota Naika</name>
      <address>
        <city>Miyazaki city</city>
        <state>Miyazaki pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etou Clinic</name>
      <address>
        <city>Nichinan city</city>
        <state>Miyazaki pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawano Clinic</name>
      <address>
        <city>Nichinan city</city>
        <state>Miyazaki pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi Clinic</name>
      <address>
        <city>Nichinan city</city>
        <state>Miyazaki pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasegawa Clinic</name>
      <address>
        <city>Nakano city</city>
        <state>Nagano pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Prefectural Gojo Hospital</name>
      <address>
        <city>Gojo city</city>
        <state>Nara pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujii Internal Medicine Clinic</name>
      <address>
        <city>Kashihara city</city>
        <state>Nara pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuoka Clinic</name>
      <address>
        <city>Kita katsuragi gun</city>
        <state>Nara pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ote Clinic of Internal</name>
      <address>
        <city>Sakurai city</city>
        <state>Nara pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uchiyama Clinic</name>
      <address>
        <city>Joetsu city</city>
        <state>Niigata pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Clinic</name>
      <address>
        <city>Niigata city</city>
        <state>Niigata pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maeda Medical Clinic</name>
      <address>
        <city>Niigata city</city>
        <state>Niigata pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishimura Clinic</name>
      <address>
        <city>Fujiidera city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoseikai Matsuda Iin</name>
      <address>
        <city>Fujiidera city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeda Clinic</name>
      <address>
        <city>Higashiosaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Clinic</name>
      <address>
        <city>Izumi city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuda Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikuhara Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawagishi-naika Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinugawa Cardiology Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kubota Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaki Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanko Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Ekisaikai Hospital</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tamatani Clinic</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Clinic</name>
      <address>
        <city>Sakai city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakao Medical Clinic</name>
      <address>
        <city>Sakai city</city>
        <state>Osaka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga Memorial Clinic</name>
      <address>
        <city>Saga city</city>
        <state>Saga pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enomoto Clinic</name>
      <address>
        <city>Ageo city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asano Internal Medicine Clinic</name>
      <address>
        <city>Kawagoe city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iryohojin Hogi Sinryojyo</name>
      <address>
        <city>Kawaguchi city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokutake Iin</name>
      <address>
        <city>Kawaguchi city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Shibuya Clinic</name>
      <address>
        <city>Kumagaya city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanaka Medical Clinic</name>
      <address>
        <city>Saitama city</city>
        <state>Saitama pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshimura Eye&amp;Internal Medical Clinic</name>
      <address>
        <city>Mishima city</city>
        <state>Shizuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Municipal Hospital</name>
      <address>
        <city>Shizuoka city</city>
        <state>Shizuoka pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takada Clinic</name>
      <address>
        <city>Tochigi city</city>
        <state>Tochigi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murakami Clinic</name>
      <address>
        <city>Anan city</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ota Clinic</name>
      <address>
        <city>Awa city</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizumi Clinic</name>
      <address>
        <city>Itano gun</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuki National Health Insurance Hospital of Minami Town</name>
      <address>
        <city>Kaifu gun</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sekishinkan Hospital</name>
      <address>
        <city>Komatsushima city</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iryohojin Tokujikai Tanaka Iin</name>
      <address>
        <city>Myozai gun</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kensei Uchimachi Clinic</name>
      <address>
        <city>Tokushima city</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yata Clinic</name>
      <address>
        <city>Yoshinogawa city</city>
        <state>Tokushima pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okudo Poly Clinic</name>
      <address>
        <city>Katsushika ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakano Sunbright Clinic</name>
      <address>
        <city>Nakano ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugawara Clinic</name>
      <address>
        <city>Nerima ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsurumachi Clinic</name>
      <address>
        <city>Setagaya ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oda Clinic</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishii Clinic</name>
      <address>
        <city>Tachikawa city</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayame Medical Clinic</name>
      <address>
        <city>Shimonoseki city</city>
        <state>Yamaguchi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuda Medical Clinic</name>
      <address>
        <city>Shimonoseki city</city>
        <state>Yamaguchi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mizumachi Medical Clinic</name>
      <address>
        <city>Shimonoseki city</city>
        <state>Yamaguchi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuroda Iin</name>
      <address>
        <city>Otsuki city</city>
        <state>Yamanashi pref.</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasue Naika</name>
      <address>
        <city>Gifu city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin Administration Group</title>
          <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in the Japan Atherosclerosis Society (JAS) Guidelines (GL) after 3 months, had the atorvastatin [ATV] dose of 20 mg.)</description>
        </group>
        <group group_id="P2">
          <title>Rosuvastatin Administration Group</title>
          <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
                <participants group_id="P2" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="514"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not performed pre-dose examination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administered prohibit prior medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin Administration Group</title>
          <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
        </group>
        <group group_id="B2">
          <title>Rosuvastatin Administration Group</title>
          <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="504"/>
            <count group_id="B2" value="514"/>
            <count group_id="B3" value="1018"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="10.6"/>
                    <measurement group_id="B2" value="66.3" spread="11.6"/>
                    <measurement group_id="B3" value="66.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="1018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin administration before entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Administered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not administered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="384"/>
                    <measurement group_id="B2" value="393"/>
                    <measurement group_id="B3" value="777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular and Cerebrovascular events before entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial infarction</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                    <measurement group_id="B2" value="507"/>
                    <measurement group_id="B3" value="1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina pectoris</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="473"/>
                    <measurement group_id="B2" value="483"/>
                    <measurement group_id="B3" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart failure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="506"/>
                    <measurement group_id="B3" value="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Revascularization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac arrhythmias</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="473"/>
                    <measurement group_id="B2" value="488"/>
                    <measurement group_id="B3" value="961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebral haemorrhage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                    <measurement group_id="B2" value="508"/>
                    <measurement group_id="B3" value="1009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebral infarction</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                    <measurement group_id="B2" value="484"/>
                    <measurement group_id="B3" value="967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transient ischaemic attack</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="510"/>
                    <measurement group_id="B3" value="1009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complications related to diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With diabetic complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without diabetic complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                    <measurement group_id="B2" value="447"/>
                    <measurement group_id="B3" value="902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic retinopathy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With diabetic retinopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without diabetic retinopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic nephropathy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With diabetic nephropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without diabetic nephropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="491"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic neuropathy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With diabetic neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without diabetic neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                    <measurement group_id="B2" value="491"/>
                    <measurement group_id="B3" value="972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic foot</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With diabetic foot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without diabetic foot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="513"/>
                    <measurement group_id="B3" value="1017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-high-density lipoprotein cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.0" spread="30.6"/>
                    <measurement group_id="B2" value="168.9" spread="35.8"/>
                    <measurement group_id="B3" value="168.9" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.6" spread="27.9"/>
                    <measurement group_id="B2" value="139.2" spread="31.9"/>
                    <measurement group_id="B3" value="139.4" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="14.6"/>
                    <measurement group_id="B2" value="54.1" spread="13.6"/>
                    <measurement group_id="B3" value="54.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol (TC)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224.8" spread="31.8"/>
                    <measurement group_id="B2" value="223.0" spread="36.0"/>
                    <measurement group_id="B3" value="223.9" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride (TG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149.6" spread="89.1"/>
                    <measurement group_id="B2" value="154.5" spread="137.1"/>
                    <measurement group_id="B3" value="152.1" spread="115.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-HDL-C/HDL-C ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25" spread="1.07"/>
                    <measurement group_id="B2" value="3.36" spread="1.31"/>
                    <measurement group_id="B3" value="3.30" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C/HDL-C ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.66" spread="0.81"/>
                    <measurement group_id="B2" value="2.73" spread="0.91"/>
                    <measurement group_id="B3" value="2.69" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free fatty acids (FFA)</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.585" spread="0.297"/>
                    <measurement group_id="B2" value="0.584" spread="0.299"/>
                    <measurement group_id="B3" value="0.584" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% (NGSP value)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.38" spread="0.59"/>
                    <measurement group_id="B2" value="6.40" spread="0.66"/>
                    <measurement group_id="B3" value="6.39" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118.8" spread="27.0"/>
                    <measurement group_id="B2" value="119.1" spread="31.2"/>
                    <measurement group_id="B3" value="118.9" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin</title>
          <units>μU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.95" spread="18.66"/>
                    <measurement group_id="B2" value="12.57" spread="20.07"/>
                    <measurement group_id="B3" value="11.77" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>1,5-anhydro-D-glucitol (1,5-AG)</title>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.40" spread="7.91"/>
                    <measurement group_id="B2" value="15.39" spread="8.10"/>
                    <measurement group_id="B3" value="15.40" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level</title>
        <time_frame>Baseline, and 12 months after administration</time_frame>
        <population>Participants in full analysis set (FAS) except the ones who had no HDL-C data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level</title>
          <population>Participants in full analysis set (FAS) except the ones who had no HDL-C data at 12 months.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.3" spread="19.1"/>
                    <measurement group_id="O2" value="-32.8" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c Level</title>
        <time_frame>Baseline, 12 months after administration</time_frame>
        <population>Participants in FAS except the ones who had no HbA1c data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Level</title>
          <population>Participants in FAS except the ones who had no HbA1c data at 12 months.</population>
          <units>Amount of change (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.120" spread="0.65"/>
                    <measurement group_id="O2" value="0.10" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Deterioration of Diabetic Treatment Status</title>
        <description>“Deterioration of diabetic treatment status” is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
        <time_frame>Baseline, 12 months after administration</time_frame>
        <population>Full analysis set - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Deterioration of Diabetic Treatment Status</title>
          <description>“Deterioration of diabetic treatment status” is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
          <population>Full analysis set - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Therapy intensification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration in HbA1c of &gt; 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status</title>
        <description>“Deterioration of diabetic treatment status” is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
        <time_frame>Baseline, 3, 6, 12 months after administration</time_frame>
        <population>Full analysis set - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status</title>
          <description>“Deterioration of diabetic treatment status” is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of &gt; 0.5%.</description>
          <population>Full analysis set - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Therapy intensification: 0-3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy intensification: 3-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy intensification: 6-12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: 0-3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: 3-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: 6-12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in 1,5-AG Level</title>
        <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <population>Participants in FAS except the ones who had no 1,5-AG data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in 1,5-AG Level</title>
          <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
          <population>Participants in FAS except the ones who had no 1,5-AG data at 12 months.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="30.8"/>
                    <measurement group_id="O2" value="5.5" spread="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="35.8"/>
                    <measurement group_id="O2" value="2.6" spread="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="35.1"/>
                    <measurement group_id="O2" value="3.5" spread="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c Level</title>
        <time_frame>Baseline, 3, 6 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <population>Full analysis set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Level</title>
          <population>Full analysis set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>Amount of change (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.42"/>
                    <measurement group_id="O2" value="0.00" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.57"/>
                    <measurement group_id="O2" value="0.12" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Blood Glucose Level (Fasting)</title>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <population>Participants in FAS except the ones who had no blood glucose level data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Blood Glucose Level (Fasting)</title>
          <population>Participants in FAS except the ones who had no blood glucose level data at 12 months.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="19.3"/>
                    <measurement group_id="O2" value="2.7" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="24.1"/>
                    <measurement group_id="O2" value="5.9" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="24.3"/>
                    <measurement group_id="O2" value="3.7" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Glucose Level (Fasting)</title>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Glucose Level (Fasting)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="24.5"/>
                    <measurement group_id="O2" value="0.1" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="30.2"/>
                    <measurement group_id="O2" value="4.3" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="30.7"/>
                    <measurement group_id="O2" value="1.5" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Insulin Level</title>
        <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa.</description>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <population>Full analysis set - All participants who received at least 1 dose of open-label study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Insulin Level</title>
          <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa.</description>
          <population>Full analysis set - All participants who received at least 1 dose of open-label study drug</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="211.2"/>
                    <measurement group_id="O2" value="31.3" spread="166.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="193.9"/>
                    <measurement group_id="O2" value="35.5" spread="142.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="132.9"/>
                    <measurement group_id="O2" value="13.8" spread="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Level</title>
        <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <population>Full analysis set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Level</title>
          <description>An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
          <population>Full analysis set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>μU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="20.26"/>
                    <measurement group_id="O2" value="-0.54" spread="18.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="18.63"/>
                    <measurement group_id="O2" value="-0.44" spread="19.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="18.69"/>
                    <measurement group_id="O2" value="-2.91" spread="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Insulin level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="18.66"/>
                    <measurement group_id="O2" value="12.57" spread="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)</title>
        <time_frame>From the start of the treatment to the end of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)</title>
          <units>Number of patients with any events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Serious Adverse Events (SAE)</title>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Serious Adverse Events (SAE)</title>
          <units>Number of patients with SAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)</title>
        <time_frame>Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment</time_frame>
        <population>Participants in FAS except the ones who had no lipids level data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)</title>
          <population>Participants in FAS except the ones who had no lipids level data at 12 months.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C: at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="19.2"/>
                    <measurement group_id="O2" value="-39.2" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.6" spread="19.4"/>
                    <measurement group_id="O2" value="-36.4" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="21.5"/>
                    <measurement group_id="O2" value="-34.7" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C: at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="14.3"/>
                    <measurement group_id="O2" value="5.6" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="15.1"/>
                    <measurement group_id="O2" value="8.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="14.7"/>
                    <measurement group_id="O2" value="7.7" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC: at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="13.3"/>
                    <measurement group_id="O2" value="-25.9" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="13.0"/>
                    <measurement group_id="O2" value="-23.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="14.3"/>
                    <measurement group_id="O2" value="-23.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="38.0"/>
                    <measurement group_id="O2" value="-11.0" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="45.9"/>
                    <measurement group_id="O2" value="-11.9" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="62.2"/>
                    <measurement group_id="O2" value="-15.9" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C/HDL-C ratio: at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="22.6"/>
                    <measurement group_id="O2" value="-37.7" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C/HDL-C ratio: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.1" spread="19.4"/>
                    <measurement group_id="O2" value="-37.2" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C/HDL-C ratio: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="22.7"/>
                    <measurement group_id="O2" value="-36.0" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA: at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="87.8"/>
                    <measurement group_id="O2" value="25.9" spread="111.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA: at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="80.5"/>
                    <measurement group_id="O2" value="15.9" spread="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FFA: at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="125.3"/>
                    <measurement group_id="O2" value="34.8" spread="111.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C Level</title>
        <time_frame>Baseline, 3 and 6 months after administration, the end of starting dose and the end of study treatment</time_frame>
        <population>Participants in FAS except the ones who had no non-HDL-C level data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C Level</title>
          <population>Participants in FAS except the ones who had no non-HDL-C level data at 12 months.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="17.6"/>
                    <measurement group_id="O2" value="-35.5" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="16.6"/>
                    <measurement group_id="O2" value="-33.5" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes in Lipids and Inflammatory Marker (Hs-CRP) and Their Correlation</title>
        <description>Correlation between percent changes in lipids (LDL-C, HDL-C, non-HDL-C, TG, non-HDL-C/HDL-C ratio, LDL-C/HDL-C ratio, TC and FFA) and inflammatory marker (hs-CRP)</description>
        <time_frame>Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007</title>
        <description>Percentage of participants achieving the target LDL-C levels &lt;100 mg/dL for participants with history of coronary artery diseases (CAD) and &lt;120 mg/dL for participants without history of CAD are presented.</description>
        <time_frame>3 months after administration, the end of starting dose and the end of study treatment</time_frame>
        <population>Full analysis set except participants who have reached the target LDL-C level specified at the treatment start</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007</title>
          <description>Percentage of participants achieving the target LDL-C levels &lt;100 mg/dL for participants with history of coronary artery diseases (CAD) and &lt;120 mg/dL for participants without history of CAD are presented.</description>
          <population>Full analysis set except participants who have reached the target LDL-C level specified at the treatment start</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="85.5" upper_limit="92.0"/>
                    <measurement group_id="O2" value="89.9" lower_limit="86.3" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At the end of study treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="82.5" upper_limit="89.6"/>
                    <measurement group_id="O2" value="87.5" lower_limit="83.7" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1,5-AG Level</title>
        <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
        <time_frame>Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin Administration Group</title>
            <description>Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin Administration Group</title>
            <description>Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1,5-AG Level</title>
          <description>An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="3.48"/>
                    <measurement group_id="O2" value="-0.21" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="4.23"/>
                    <measurement group_id="O2" value="-0.94" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="4.33"/>
                    <measurement group_id="O2" value="-1.09" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 1,5-AG level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.40" spread="7.91"/>
                    <measurement group_id="O2" value="15.39" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At the start of the treatment, 3, 6, and 12 months after administration</time_frame>
      <desc>Analyzed: Safety analysis set - all participants who received at least 1 dose of open-label study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin Administration Group</title>
          <description>Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.)</description>
        </group>
        <group group_id="E2">
          <title>Rosuvastatin Administration Group</title>
          <description>Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Keratitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Rectal polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hypocholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Atonic urinary bladder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hisao Ogawa, Ph.D; Study Chair</name_or_title>
      <organization>Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University</organization>
      <phone>+ 81 963735175</phone>
      <email>ogawah@kumamoto-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

